Research has shown that several downstream targets of FOXM1, including survivin, cyclin B1, S-Phase Kinase-Associated Protein 2, and CDC25B, were significantly upregulated in non-small-cell lung cancer cells treated with gefitinib [39]. This evidence concerns the gene SKP2 and non-small cell lung carcinoma.